Therapy News and Research

RSS

Scientists identify new treatment target for squamous cell lung cancer

Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

Scientists identify novel gene markers for EGFR inhibition in patients

Scientists are continuing their work on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial — known more commonly as the BATTLE trial — and presented updated results at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Scientists uncover genetic characteristic of metastatic prostate cancer

Scientists have uncovered a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. These findings are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, which will debut at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Positive results from Abbott's ABSORB device trial in coronary artery disease

Abbott today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold for the treatment of coronary artery disease.

4 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

Scientists identify digoxin as possible therapy for prostate cancer

Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.

4 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Two experts to comment on new transcatheter heart valve studies

New transcatheter heart valve studies will be presented at the American College of Cardiology meeting in New Orleans on April 3 and 4. The studies compare patient outcomes from minimally invasive catheter procedures with those from open-heart surgery.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

PLC Systems Inc., a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be presented at 11:57 a.m. CT on Monday, April 4, 2011, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Additionally, PLC will be demonstrating RenalGuard at its booth at the conference.

2 Apr 2011

CarePoint Partners launches "Got Food?" campaign

CarePoint Partners, one of the largest, fastest growing independent home infusion therapy companies in the United States, launched a food drive today throughout its twenty-one locations in eight states to help the less fortunate in the communities where it operates.

2 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

Lindt USA announces winners of 2011 Lindt Unsung Heroes of Autism

To help kick off National Autism Awareness Month, premium Swiss chocolatier, Lindt USA announces today the 2011 Lindt Unsung Heroes of Autism honorees: Kerri Duncan of Springfield, Mo., Connie Erbert of Wichita, Kan., and Bonnie Gillman of Tustin, Calif.

2 Apr 2011